SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Innoviva, Inc., et al. – ‘SC TO-T’ on 7/25/22 re: La Jolla Pharmaceutical Co. – ‘EX-FILING FEES’

On:  Monday, 7/25/22, at 8:34am ET   ·   Accession #:  1193125-22-200490   ·   File #:  5-44849

Previous ‘SC TO-T’:  ‘SC TO-T/A’ on 7/8/22   ·   Next:  ‘SC TO-T/A’ on 8/16/22   ·   Latest:  ‘SC TO-T/A’ on 8/22/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/25/22  Innoviva, Inc.                    SC TO-T                8:882K La Jolla Pharmaceutical Co.       Donnelley … Solutions/FA
          Innoviva Acquisition Sub, Inc.

Tender-Offer Statement by a Third Party   —   Schedule TO

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC TO-T     Tender-Offer Statement by a Third Party             HTML     41K 
 8: EX-FILING FEES  Filing Fees                                     HTML     12K 
 2: EX-99.(A)(1)(A)  Exhibit (A)(1)(A)                              HTML    528K 
 3: EX-99.(A)(1)(B)  Exhibit (A)(1)(B)                              HTML    155K 
 4: EX-99.(A)(1)(C)  Exhibit (A)(1)(C)                              HTML     13K 
 5: EX-99.(A)(1)(D)  Exhibit (A)(1)(D)                              HTML     18K 
 6: EX-99.(A)(1)(E)  Exhibit (A)(1)(E)                              HTML     27K 
 7: EX-99.(D)(3)  Exhibit (D)(3)                                    HTML     26K 


‘EX-FILING FEES’   —   Filing Fees


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-FILING FEES  

Exhibit 107

Calculation of Filing Fee Table

Table 1: Transaction Valuation

 

     

Transaction

Valuation

  

Fee

rate

  

Amount of

Filing Fee

Fees to Be Paid

   $216,757,957.30(1)    0.00927%    $20,093.46(2)

Fees Previously Paid

   $0.00         $0.00

Total Transaction Valuation

   $216,757,957.30          

Total Fees Due for Filing

             $20,093.46

Total Fees Previously Paid

             $0.00

Total Fee Offsets

             $0.00

Net Fee Due

             $20,093.46

 

(1)

For purposes of calculating the filing fee pursuant to Rule 0-11(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Transaction Valuation was calculated by multiplying (a) $6.23, the tender offer price per Share (as defined below), by (b) the sum of (i) 24,926,469 shares of common stock, par value $0.0001 per share (the “Shares”), of La Jolla Pharmaceutical Company (“La Jolla”), (ii) 3,906.51922572953 shares of Series C-12 Preferred Stock, (iii) 6,417,267 Shares subject to issuance pursuant to options granted by La Jolla under La Jolla’s Amended and Restated 2013 Equity Incentive Plan (as amended through the date hereof) (the “Option Plan”) and (iv) 3,182,733 Shares reserved for future issuance under the Option Plan. The foregoing share figures have been provided by the issuer to the offerors and are as of July 21, 2022, the most recent practicable date.

(2)

The amount of the filing fee, calculated in accordance with Exchange Act Rule 0-11(b)(1) and the Securities and Exchange Commission Fee Rate Advisory #1 for Fiscal Year 2022, was calculated by multiplying $216,757,957.30 by 0.0000927.


Dates Referenced Herein

This ‘SC TO-T’ Filing    Date    Other Filings
Filed on:7/25/22None on these Dates
7/21/22
 List all Filings 
Top
Filing Submission 0001193125-22-200490   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 10:53:11.1pm ET